Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: Mutations and Mechanisms of Resistance Medscape InDiscussion: Mantle Cell Lymphoma

Drs Peter Martin and Anita Kumar discuss covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors in the frontline setting, BTK mutations, and the complicated mechanisms of resistance.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982893). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Long-term Follow-up of MCL Patients Treated With Single-Agent Ibrutinib: Updated Safety and Efficacy Results https://pubmed.ncbi.nlm.nih.gov/26059948/
Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma (ACE-LY-004): A Single-Arm, Multicentre, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/29241979/
Treatment of Patients With Relapsed or Refractory Mantle-Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase https://pubmed.ncbi.nlm.nih.gov/32461234/
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects https://pubmed.ncbi.nlm.nih.gov/33777941/
The Potential of Pirtobrutinib in Multiple B-cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35747462/
Pirtobrutinib in Relapsed or Refractory B-cell Malignancies (BRUIN): A Phase 1/2 Study https://pubmed.ncbi.nlm.nih.gov/33676628/
Postibrutinib Outcomes in Patients With Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/26764355/
Genetic Heterogeneity in Primary and Relapsed Mantle Cell Lymphomas: Impact of Recurrent CARD11 Mutations https://pubmed.ncbi.nlm.nih.gov/27224912/
NF-κB Signaling and Its Relevance to the Treatment of Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29907126/
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors https://pubmed.ncbi.nlm.nih.gov/35196427/
Ibrutinib Plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35657079/
Efficacy and Safety of Ibrutinib Combined With Standard First-line Treatment or as Substitute for Autologous Stem Cell Transplantation in Younger Patients With Mantle Cell Lymphoma: Results From the Randomized Triangle Trial by the European MCL Network https://ashpublications.org/blood/article/140/Supplement%201/1/490022/Efficacy-and-Safety-of-Ibrutinib-Combined-with
Zanubrutinib, Obinutuzumab, and Venetoclax With Minimal Residual Disease-Driven Discontinuation in Previously Untreated Patients With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: A Multicentre, Single-arm, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/34826411/
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia https://www.mskcc.org/cancer-care/clinical-trials/18-427
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma https://clinicaltrials.gov/ct2/show/NCT03223610
Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) With Real-time Monitoring of MRD in Patients With Treatment-Naïve Mantle Cell Lymphoma https://ashpublications.org/blood/article/140/Supplement%201/175/489040/Phase-2-Trial-of-Acalabrutinib-Lenalidomide
A Phase III Study of Zanubrutinib Plus Rituximab Versus Bendamustine Plus Rituximab in Transplant-Ineligible, Untreated Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/32985902/
A Study Looking at Ibrutinib for Older People With Mantle Cell Lymphoma (ENRICH) https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-ibrutinib-for-older-people-with-mantle-cell-lymphoma-enrich
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts https://pubmed.ncbi.nlm.nih.gov/35763708/